Download the full-sized PDF of Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?Download the full-sized PDF



Permanent link (DOI):


Export to: EndNote  |  Zotero  |  Mendeley


This file is in the following communities:

Agricultural, Food and Nutritional Science, Department of


This file is in the following collections:

Journal Articles (Agricultural, Food and Nutritional Science)

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Open Access


Author or creator
Fogelman, D.
Holmes, H.
Khalil, M.
Katz, M. H.
Prado, C. M.
Lieffers, J.
Varadhachary, G. R.
Shroff, R.
Overman, M. J.
Javle, M.
Additional contributors
Insulin Growth Factor
Pancreatic Cancer
Type of item
Journal Article (Published)
BackgroundIGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.MethodsWe evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK-0646 (M), a monoclonal antibody directed against the IGF-1 protein, in patients with metastatic pancreatic cancer (MPC). Two different doses of M were tested, 5 and 10 mg/kg. We used the Slice-o-matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm2) at baseline and after 2 and 4 months of treatment. Patients received either gemcitabine with erlotinib (G + E), G + E + M, or G + M. Differences between the groups were compared using t tests.ResultsFifty-three patients had both baseline and 2-month imaging available for analysis. Of these, 42 received M with their chemo, and 11 had G + E only. After 2 months of treatment, both groups demonstrated decrease in muscle mass. G + E patients lost 5.6 % of muscle mass; M patients lost 9.1 and 8.6 % after treatment with 5 and 10 mg/kg, respectively (p = 0.53). Patients demonstrating a response lost less muscle (median 4.6 %) than those with stable disease (9.6 %) and progressive disease (8.9 %, p = 0.14). Muscle retention from baseline to 2-month imaging, defined as loss of <6 cm2 of muscle, correlated with better survival than those patients demonstrating a muscle loss (HR 0.51, p = 0.03).ConclusionsMPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop-out and death. There was a non-significant trend toward greater muscle mass loss in patients on anti-IGF-1R therapy. However, it is unclear if this loss translates into functional differences between patients.
Date created
License information

Attribution-NonCommercial 4.0 International
Citation for previous publication
Fogelman, D., Holmes, H., Khalil, M., Katz, M. H., Prado, C. M., Lieffers, J., Varadhachary, G. R., Shroff, R., Overman, M. J., & Javle, M. (2014). Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Journal of Cachexia, Sarcopenia and Muscle, 5(4), 307-313.


Link to related item

File Details

Date Uploaded
Date Modified
Audit Status
Audits have not yet been run on this file.
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 273916
Last modified: 2017:09:06 16:29:01-06:00
Filename: JCSM_5_4_307.pdf
Original checksum: 78c5af33a8d086f29ccb86be90657218
Activity of users you follow
User Activity Date